HomeComparePBB vs MRK

PBB vs MRK: Dividend Comparison 2026

PBB yields 7.92% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBB wins by $3.0K in total portfolio value
10 years
PBB
PBB
● Live price
7.92%
Share price
$25.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.8K
Annual income
$1,306.98
Full PBB calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — PBB vs MRK

📍 PBB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBBMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBB + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBB pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBB
Annual income on $10K today (after 15% tax)
$673.00/yr
After 10yr DRIP, annual income (after tax)
$1,110.93/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, PBB beats the other by $303.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBB + MRK for your $10,000?

PBB: 50%MRK: 50%
100% MRK50/50100% PBB
Portfolio after 10yr
$32.3K
Annual income
$1,128.64/yr
Blended yield
3.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PBB
Analyst Ratings
1
Sell
Consensus: Sell
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBB buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBBMRK
Forward yield7.92%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$33.8K$30.7K
Annual income after 10y$1,306.98$950.29
Total dividends collected$10.5K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: PBB vs MRK ($10,000, DRIP)

YearPBB PortfolioPBB Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,492$791.77$11,192$351.54+$300.00PBB
2$13,147$850.35$12,524$392.70+$623.00PBB
3$14,976$909.16$14,015$438.65+$961.00PBB
4$16,992$967.92$15,682$489.96+$1.3KPBB
5$19,208$1,026.39$17,547$547.23+$1.7KPBB
6$21,637$1,084.33$19,632$611.16+$2.0KPBB
7$24,293$1,141.54$21,963$682.53+$2.3KPBB
8$27,191$1,197.82$24,571$762.18+$2.6KPBB
9$30,348$1,253.02$27,486$851.08+$2.9KPBB
10$33,779$1,306.98$30,745$950.29+$3.0KPBB

PBB vs MRK: Complete Analysis 2026

PBBStock

PBB is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in PBB shares.

Full PBB Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this PBB vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBB vs SCHDPBB vs JEPIPBB vs OPBB vs KOPBB vs MAINPBB vs JNJPBB vs ABBVPBB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.